Process options in hepatitis B surface antigen extraction from transgenic potato

被引:16
作者
Dogan, B
Mason, HS
Richter, L
Hunter, JB
Shuler, ML [1 ]
机构
[1] Cornell Univ, Sch Chem Engn, Ithaca, NY 14853 USA
[2] Cornell Univ, Dept Food Sci, Boyce Thompson Inst, Dept Agr & Biol Engn, Ithaca, NY 14853 USA
关键词
D O I
10.1021/bp0000454
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The process conditions for recombinant hepatitis B surface antigen (HBsAg) extraction from transgenic potato were examined. The effects of temperature, the reducing agent P-mercaptoethanol (BME), and proteinase inhibitors on the level of antigenic activity of recovered HBsAg were determined. Sedimentation profiles were performed to characterize HBsAg assembly into virus-like particles. Increasing the temperature of the sample for about 1 min increased the measured HBsAg antigenic activity. The optimum temperature was around 50 degrees C. A 3-fold enhancement of the antigenic activity was obtained in extract from transgenic potato expressing HBsAg, when monoclonal antibodies were used to assay for HBsAg. When antigenic activity was determined by polyclonal antibodies, no enhancement in the antigenic activity was obtained. Temperature may affect the conformation of the a epitope to which the monoclonal antibodies bind or alter the fluidity of surface lipid regions. BME increased the antigenic activity of HBsAg up to 4-fold when monoclonal antibodies directed against the a determinant were used, but there was no increase with polyclonal antibodies. This observation suggests that BME affects the structure or presentation of the a epitope. In the presence of BME and leupeptin, a proteinase inhibitor, higher antigenic activity was obtained. Leupeptin might protect the antigen, which might become more susceptible to proteolytic degradation after reduction, as a result of stimulation of sulfhydryl proteases. Although both temperature and BME increased the antigenic activity of HBsAg individually, when combined their interaction was antagonistic, resulting in reduced antigenic activity. Different proteinase inhibitors, including leupeptin, aprotinin, E-64, pefabloc, and pepstatin, had no significant effect on HBsAg from potato extract in a 2 h period in the absence of BME. The sedimentation profile of potato-produced HBsAg was determined in 5-30% sucrose gradients. Yeast-derived recombinant HBsAg was used as a positive control. The HBsAg from transgenic potato showed sedimentation and density properties that are very similar to the yeast-produced antigen, indicating assembly into virus-like particles. BME treatment did not change the sedimentation profile.
引用
收藏
页码:435 / 441
页数:7
相关论文
共 20 条
  • [1] MUTATIONS OF SOME CRITICAL AMINO-ACID-RESIDUES IN THE HEPATITIS-B VIRUS SURFACE-ANTIGEN
    BRUCE, SA
    MURRAY, K
    [J]. JOURNAL OF MEDICAL VIROLOGY, 1995, 46 (02) : 157 - 161
  • [2] Process and economic evaluation of the extraction and purification of recombinant β-glucuronidase from transgenic corn
    Evangelista, RL
    Kusnadi, AR
    Howard, JA
    Nikolov, ZL
    [J]. BIOTECHNOLOGY PROGRESS, 1998, 14 (04) : 607 - 614
  • [3] HEPATITIS-B SURFACE-ANTIGEN - ROLE OF LIPIDS IN MAINTAINING THE STRUCTURAL AND ANTIGENIC PROPERTIES OF PROTEIN-COMPONENTS
    GAVILANES, F
    GOMEZGUTIERREZ, J
    ARACIL, M
    GONZALEZROS, JM
    FERRAGUT, JA
    GUERRERO, E
    PETERSON, DL
    [J]. BIOCHEMICAL JOURNAL, 1990, 265 (03) : 857 - 864
  • [4] GAVILANES F, 1982, J BIOL CHEM, V257, P7770
  • [5] THERMAL-STABILITY OF HEPATITIS-B SURFACE ANTIGEN-S PROTEINS
    GOMEZGUTIERREZ, J
    RODRIGUEZCRESPO, I
    GONZALEZROS, JM
    FERRAGUT, JA
    PAUL, DA
    PETERSON, DL
    GAVILANES, F
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA, 1992, 1119 (03) : 225 - 231
  • [6] GUERRERO E, 1988, VIRAL HEPATITIS LIVE, P606
  • [7] HEPATITIS-B SURFACE-ANTIGEN ASSEMBLIES IN A POST-ER, PRE-GOLGI COMPARTMENT
    HUOVILA, APJ
    EDER, AM
    FULLER, SD
    [J]. JOURNAL OF CELL BIOLOGY, 1992, 118 (06) : 1305 - 1320
  • [8] KANE M, 1995, VACCINE, V13, pS16
  • [9] SUBTYPES OF HEPATITIS-B ANTIGEN - CLINICAL RELEVANCE
    LEBOUVIER, GL
    [J]. ANNALS OF INTERNAL MEDICINE, 1973, 79 (06) : 894 - 896
  • [10] Drug therapy - Vaccines to prevent viral hepatitis
    Lemon, SM
    Thomas, DL
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (03) : 196 - 204